Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors

摘要: BACKGROUND: Multiple myeloma (MM) is still a fatal plasma cell cancer. Novel compounds are currently clinically tested as single agent in relapsing patients, but best cases with partial response of fraction emphasising the need to design tools predicting drug efficacy. Histone deacetylase inhibitors (HDACi) anticancer agents targeting epigenetic regulation gene expression and clinical development MM. METHODS: To create score HDACi efficacy, five MM lines were treated trichostatin A (TSA) profiles determined. RESULTS: The 95 genes was found be upregulated by TSA, using paired supervised analysis Significance Analysis Microarrays software. Thirty-seven these had prognostic value for overall survival cohort 206 newly diagnosed patients their information summed up histone acetylation (HA Score); highest HA Score shorter survival. It worth noting that or patients' primary cells high significant higher sensitivity valproic acid, panobinostat vorinostat. CONCLUSION: In conclusion, allows identification poor survival, who could benefit from treatment.